Takeda gets FDA breakthrough therapy status for pevonedistat to treat higher-risk HR-MDS

The head office of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan (Credit: GFDL, Cc-by-sa-2.5)